Through
4/26
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments, and is safe for patients.
A “nudge” is helping shorten treatment time for patients with advanced cancer, with less frequent palliative radiation therapy sessions.
A Penn study of Medicare patients who are often underrepresented in medical trials finds overall survival benefits from treatment with targeted therapies.
New Bolton Center’s Daniela Luethy’s research on 15 horses with lymphoma concluded that chemotherapy had encouraging results. Her study poses opportunities for further research with more case control.
A Penn study has identified a protein called TOX that regulates exhausted T-cells, and could be a key to new immunotherapies.
The online source for cancer information turns 25. Last year alone, the website had 4.5 million visits, with half from other countries, and nurses looking for reliable material to educate patients.
For dogs with mammary tumors, a course of treatment can depend on a variety of factors, some of which may seem to contradict one another. A new system developed by Penn Vet’s Karin Sorenmo and colleagues can make determining a prognosis and making treatment decisions an easier task.
New research could shape treatment strategies and clinical trial design for patients with BRCA1 and BRCA2-related breast cancers.
In the largest study of its kind, Penn researchers compare overall adverse events of proton and photon therapies.
New research from Penn Medicine overturns what was previously known about a compound associated with reductions in obesity and diabetes risk.
A 2020 study from the Perelman School of Medicine found that a blood test to screen for certain biomarkers associated with pancreatic cancer was 92% accurate in its ability to detect disease.
FULL STORY →
A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors.
FULL STORY →
A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer.
FULL STORY →
Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center.
FULL STORY →
Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy.
FULL STORY →
The Abramson Cancer Center is attempting to address one of the most common challenges cancer patients face: lack of transportation to critically important appointments. Robert Vonderheide and Carmen Guerra of the Perelman School of Medicine are quoted on the Ride Health initiative.
FULL STORY →